Development and Characterization of pFluor50, a Fluorogenic-Based Kinetic Assay System for High-Throughput Inhibition
Pratik Shriwas1, Andre Revnew1, Sarah Roo1
1Division of Medical Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
Molecules (Basel, Switzerland)
|May 14, 2025
Summary
A new assay, pFluor50, enables high-throughput screening of drug candidates for cytochrome P450 (CYP) interactions. This fluorogenic kinetic assay efficiently characterizes CYP inhibition and activation, aiding drug development.
Area of Science:
- Biochemistry
- Pharmacology
- Drug Development
Background:
- Cytochrome P450 enzymes (CYPs) are crucial for drug and xenobiotic metabolism in humans.
- Understanding CYP inhibition and activation is vital for safe and effective drug development.
- Existing assays may lack high-throughput capabilities or comprehensive CYP coverage.
Purpose of the Study:
- To develop a high-throughput, fluorogenic kinetic assay for evaluating drug interactions with major human CYPs.
- To characterize enzyme kinetics (KM, Vmax) and inhibition profiles of potential therapeutic agents.
- To enable detailed analysis of CYP inhibition types, including time-dependent and mechanism-based inhibition.
Main Methods:
- Development of a 384-well microtiter plate-based assay system (pFluor50).
- Utilized fluorogenic substrates metabolized by six key human CYP enzymes.
- Determined Michaelis-Menten kinetics and assessed inhibitor effects, including time-dependent inhibition.
Main Results:
- The pFluor50 assay successfully determined kinetic parameters (KM, Vmax) for substrate-CYP pairs.
- The assay effectively elucidated inhibition types and time-dependent inhibition for various inhibitors.
- Demonstrated utility in characterizing mechanism-based inhibition of human CYPs.
Conclusions:
- The pFluor50 assay system provides a robust, high-throughput method for drug-CYP interaction studies.
- Utilizes commercially available components for broad accessibility in drug discovery.
- Facilitates efficient screening and characterization of therapeutic candidates against prevalent human CYPs.
